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Abstract
Background: Hepatitis C virus (HCV) is a growing public health problem with a large disease burden worldwide. In
China many people living with HCV are unaware of their hepatitis status and not connected to care and treatment.
Crowdsourcing is a technique that invites the public to create health promotion materials and has been found to
increase HIV testing uptake, including in China. This trial aims to evaluate crowdsourcing as a strategy to improve
HCV awareness, testing and linkage-to-care in China.
Methods: A randomized controlled, two-armed trial (RCT) is being conducted in Shenzhen with 1006 participants
recruited from primary care sectors of The University of Hong Kong-Shenzhen Hospital. Eligible participants are ≥30
years old; a resident in Shenzhen for at least one month after recruitment; no screening for HCV within the past 12
months and not known to have chronic HCV; and, having a WeChat social media account. Allocation is 1:1. Both
groups will be administered a baseline and a follow-up survey (4-week post-enrollment). The intervention group
will receive crowdsourcing materials to promote HCV testing once a week for two weeks and feedback will be
collected thereafter, while the control group will receive no promotional materials. Feedback collected will be
judged by a panel and selected to be implemented to improve the intervention continuously.
Those identified positive for HCV antibodies will be referred to gastroenterologists for confirmation and treatment.
The primary outcome will be confirmed HCV testing uptake, and secondary outcomes include HCV confirmatory
testing and initiation of HCV treatment with follow-ups with specialist providers. Data will be collected on Survey
Star@ via mobile devices.
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Discussion: This will be the first study to evaluate the impact of crowdsourcing to improve viral hepatitis testing
and linkage-to-care in the health facilities. This RCT will contribute to the existing literature on interventions to
improve viral hepatitis testing in primary care setting, and inform future strategies to improve HCV care training for
primary care providers in China.
Trial registration: Chinese Clinical Trial Registry. ChiCTR1900025771. Registered September 7th, 2019, http://www.
chictr.org.cn/showprojen.aspx?proj=42788
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Background
Hepatitis C Virus (HCV) is a growing global health
problem, with 71 million people estimated living with
chronic HCV infection worldwide in 2015 [1]. The glo-
bal number of deaths due to HCV increased from 333,
000 in 1990 to 704,000 in 2013 [2], and it is estimated
that HCV-related mortality will triple by 2025 [3]. In
China, it is estimated that at least 8.9 million people are
living with an identified chronic HCV infection [4].
Notwithstanding, China has the largest burden of liver
cancer, accounting to 51% of all global liver cancer death
[4]. If untreated, HCV infection can lead to advanced
liver diseases, including cirrhosis, liver failure, and
hepatocellular carcinoma [5]. In the current era of direct
acting antivirals, early testing and treatment can effect-
ively cure HCV and effectively reduce hepatitis-related
mortality [6].
Low testing rate and poor linkage to care are key bar-
riers to HCV treatment in China. Since 2018, direct act-
ing antivirals (DAA) regimens such as sofosbuvir/
velpatasvir (SOF/VEL) have been included in the na-
tional recommended list of essential medications in the
China National Formulary (CNF) and have become ac-
cessible to patients with a diagnosis. However, only 18%
of the HCV-infected population in China had been diag-
nosed and less than 1.3% actually received treatment [7].
In China, HCV is primarily diagnosed by passive detec-
tion, a surveillance system targeting patients seeking care
for other illnesses apart from hepatitis, such as enrolled
into the hospital for a procedure or surgical intervention,
contributing to an underestimation of the actual number
of HCV-infected population. Additionally, HCV anti-
body detection methods and instruments are found to
be inconsistent across hospitals. Weakly positive results
were considered to be negative, hence, the reported anti-
HCV positive rate was slightly lower than the actual
level [8]. This may result to an incomplete confirmatory
testing since approximately 25–30% of antibody positive
will not experience any chronic infection [8].
Promotion of testing and subsequent linkage-to-care
service are crucial for effectively curbing the spread of
viral hepatitis as well as hepatitis-related morbidity and
mortality in China. However, patients are often lost in
labyrinth of the Chinese healthcare system and are un-
able to obtain appropriate screening and treatment. Pri-
mary healthcare providers have reported that the lack of
motivation and specific training hinder their eagerness
to provide HCV testing and treatment to patients, espe-
cially in the primary care settings in China [9]. As a re-
sult, voluntary HCV testing rates across China are low
and HCV services are underutilized despite a huge drop
in the pricing of the treatment in the last year.
Crowdsourcing is a form of community engagement
which invites the public for brainstorming of ideas and
then promotes the solutions with the public audience [10].
It has the potential to expand the role of primary care in
promoting viral hepatitis testing and care continuum in
China, which will improve healthcare access for the
millions of individuals infected with HCV (see Fig. 1). Fur-
ther, research has shown great beneficial effects by
employing crowdsourcing technique in healthcare setting-
materials developed through crowdsourcing increased
Human Immunodeficiency Virus (HIV) testing uptake
and condom use [11, 12]. In addition, social media cam-
paigns that involve active community participation have
been associated with higher rates of HIV and sexually
transmitted infection (STI) testing compared to passive
testing campaigns [13, 14]. Data from 100 Chinese indi-
viduals showed that a crowdsourced intervention of im-
ages and videos substantially increased HBV testing
compared to the standard of care (37.5% HBV testing in
the intervention arm, 14.3% testing in the standard of care
arm, OR 3.60, 95% CI 1.10–11.74) [15].
Objectives
The current study aims to compare the effects of a
crowdsourcing intervention to the control on HCV test
uptake among patients attending the primary care de-
partments in a tertiary hospital in China. The hypothesis
is that the crowdsourced intervention will be superior to
the control in promoting HCV test uptake among pa-
tients attending the primary care departments in a ter-
tiary hospital in China.
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Methods
Study design
This study will include: a pilot study to test the feasibil-
ity of participant recruitment in a tertiary hospital in
Shenzhen and the social media-based intervention deliv-
ered on smartphones; a randomized controlled trial
(RCT) to investigate the effectiveness of a crowdsourced
intervention compared to no intervention (standard-of-
care) in increasing HCV test uptake and linkage-to-care
i.e. patients found to be positive for HCV will be referred
onto the Division of Gastroenterology of HKU-SZH for
further management, if agreeable to the patients.
Study setting
All phases of this study is conducted through the Uni-
versity of Hong Kong-Shenzhen Hospital (HKU-SZH) in
Shenzhen, China. HKU-SZH was established in 2012 as
an affiliated hospital of the University of Hong Kong.
The hospital has comprehensive clinical services and re-
ported 1.52 million outpatient visits and 65,856 inpatient
discharges in 2019. With a “smart hospital” policy in
which all appointment bookings, payments, and labora-
tory results can be processed by each patient’s personal
smartphone, HKU-SZH is equipped to implement
technology-based interventions.
The city of Shenzhen is located in southern China bor-
dering Hong Kong. Internal migrants from across China
are drawn to Shenzhen by the unique economic oppor-
tunities of this fast-growing city [16]. A meta-analysis
found increased rates of infectious disease, in particular
HCV, in Chinese rural-to-urban migrants [17], making
Shenzhen a particularly crucial region for increasing
viral hepatitis awareness and improving access to care.
We will work primarily with two outpatient depart-
ments at HKU-SZH: the Department of Family Medicine
and Primary Care (FMPC) and the Division of Gastro-
enterology under the Department of Medicine. FMPC
currently draws 100,000 patient visits per year from the
municipality of Shenzhen, Guangdong as well as nearby
provinces. The Division of Gastroenterology currently
draws about 60,000 outpatient visits and 2500 inpatient
discharges per year, including patients with chronic liver
disease and viral hepatitis.
Recruitment
Recruitment will continue until 1006 eligible subjects
are enrolled. The primary recruitment sites will be
FMPC clinic rooms, as well as the endoscopy suite of
HKU-SZH, which performs 22,000 endoscopies per year.
Patients will be recruited by physicians during their
clinic or endoscopy suite visit. HCV screening at endos-
copy suites in the United States has been shown to in-
crease HCV testing uptake by threefold [18]. In China,
there is evidence that the reported prevalence of HCV
increases with age, and individuals above the age of 30
years have seen an increase in reported incidence from
passive HCV detection [19].
Eligibility criteria
Prior to enrollment, potential participants must first
complete an informed consent form in Chinese lan-
guage, which explains the purpose of the study as well as
the rights and responsibilities of the subject participants.
Participants are invited to participate if they are 30 years
old or older, have Chinese nationality, and will reside in
Shenzhen for the following month. Participants will be
excluded if they self-report one of the followings: known
chronic HCV infection, testing for serum anti-HCV in
the past 12 months, current or planned pregnancy, cur-
rently undergoing complex medical treatment for other
conditions. All eligible participants must provide a work-
ing unique mobile phone number and a WeChat ac-
count to be enrolled. Wechat is currently the most
popular messaging social media app in China, with more
than 1 billion active users and 45 billion daily text mes-
sages according to the statistics shown in [20].
Fig. 1 Crowdsourcing: the “bottom-up” approach to solicit ideas on HCV testing and linkage to care
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Sample size
The anti-HCV seroprevalence in China is estimated to
be between 2.2 to 3.7%, giving an average of 3% preva-
lence of anti-HCV in the recruited population [21, 22].
The testing rate of conventional public health marketing
methods (messages created by public health profes-
sionals) is approximately 35% [14]. If we conservatively
assume crowdsourcing improves testing rates by 10%,
together with 90% power and an alpha risk of 5%, a sam-
ple size of 1006 patients (n = 503 in each arm) will be
required.
Randomization and allocation
Once they have signed the consent form, participants
will be randomly allocated on a 1:1 ratio to either the
intervention or control group through a randomization
procedure using permuted blocks. SAS software (Cary,
North Carolina, USA) will be used to create the alloca-
tion sequence using PROC PLAN and RANUNI func-
tions. Participants will be allocated sequentially in the
order in which they are enrolled. This study will be not
be blinded, since participants will know their
randomization assignment based on whether they re-
ceive the intervention, and investigators will be aware of
the randomization assignment.
Intervention
The crowdsourcing intervention is composed of two
parts: 1) promotional materials developed through a
nation-wide open contest in China, 2) a series of mini
crowdsourcing contests to solicit participant feedback to
improve the promotional materials. The impact of
crowdsourcing is expected through both receiving the
crowdsourced messages and actively engaging with the
message.
Upon enrollment, participants will be required to add
the designated study account as a WeChat contact. The
study account will be monitored and maintained by the
researchers. The intervention materials—two videos and
two images designed to increase awareness about
HCV—will be delivered to participants over the course
of 2 weeks as individual messages. The initial materials
were developed through a nation-wide open contest in
China, and was previously evaluated for hepatitis testing
uptake in men-who-have-sex-with-men (MSM) in
China [15].
Next, participants will be asked whether they have ex-
pertise in the following fields: healthcare, social media,
or education. Participants who have expertise will be
asked to reflect on the intervention based on their ex-
pertise, while participants without expertise will be en-
couraged to reflect based on personal experience. All
participants will be invited to submit 50- to 200-
character suggestion on how to improve the intervention
materials. Submissions will be judged by a panel of
health workers, researchers, and community advocates
on the following: [1] potential to encourage HCV testing
[2]; creativity [3]; potential to engage social media users;
and [4] feasibility in clinical settings in Shenzhen. Sug-
gestions for improvement will be shared anonymously
among agreeable participants who are receptive to re-
ceive frequent updates from WeChat. Top scoring sug-
gestions that meet the predesignated standard will
receive cash prizes up to 500 Chinese yuan (72.5 USD).
Feasible suggestions will be incorporated into the inter-
vention materials and presented to the next round of
participants.
Participants in the control arm will only receive the
baseline and follow-up surveys via WeChat. They will
not receive any promotional materials as there are cur-
rently no materials used in standard-of-care HCV testing
promotion at the hospital. In the final week of the inter-
vention period, all participants will receive a reminder to
obtain HCV testing and a follow-up survey.
Linkage-to-care for HCV at HKU-SZH
During the four-week intervention period, participants
tested positive for HCV antibody screening test will be
referred to Department of Gastroenterology at the hos-
pital. Blood tests will be collected for HCV confirmatory
testing, and the participant will be informed of the test
results within five working days. Those who have con-
firmed HCV infection via HCV RNA testing (Abbott
Laboratories, lower limit of detection 15 IU/mL), re-
spectively, will be referred to HKU-SZH’s specialty Liver
Clinic in the Department of Gastroenterology for further
diagnostic workup (liver biochemistry, ultrasonography,
transient elastography, genotyping) and discussion of
direct-acting antiviral treatment. Sovaldi-based treat-
ment will be discussed, which will be replaced by
Epclusa-based treatment when available. Patients will
then be monitor for sustained virological response. After
successful eradication, patients with cirrhosis or ad-
vanced fibrosis will continue follow-up at the HKU-SZH
Liver Clinic, while those with non-advanced fibrosis will
be referred to FMPC for follow-up. Participants that ob-
tain anti-HCV testing or HCV RNA confirmatory testing
at any facility in Shenzhen will be reimbursed for testing
costs if they are able to provide medical records for
confirmation.
Pilot study
Thirty participants will be recruited for the pilot to
evaluate on the feasibility intervention delivery via
WeChat and the participatory and iterative components
of the intervention package. In addition, the pilot will in-
form the expected rate of recruitment, rate of participant
retention from completion of the baseline survey to
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HCV testing uptake, and rate of linkage-to-care. At the
end of the pilot period, participants will be asked to pro-
vide feedback on the trial design.
Outcomes
The primary outcome is the number of anti-HCV
screening tests completed by participants in either RCT
arm within 4 weeks after enrollment. This dichotomous
outcome will be determined by a single endpoint: uptake
of HCV antibody screening test. Participants will only be
counted as achieving the primary outcome if medical re-
cords at HKU-SZH or in another facility in Shenzhen
confirm that they had tested for HCV during the inter-
vention period. Medical records would be assessed based
on either the administrative record or photo verification
of official testing record.
Secondary outcomes are as follows: rate of participa-
tion in the crowdsourcing intervention; content of
feedback submissions; number of participants that self-
report HCV antibody testing but are not confirmed by
medical records; number of participants that follow-up
for HCV confirmatory testing; number of HCV diag-
nosed participants to continue with anti-HCV treatment,
versus those who decline treatment for any reason; num-
ber of participants that will be completely cured of HCV
infection, versus number that drop out prior to complet-
ing treatment; number of participants diagnosed with
chronic liver disease (including cirrhosis, liver failure, or
hepatocellular carcinoma); number of participants that
will return to primary care for chronic liver disease
follow-up or future screening of HCV and other condi-
tions. Definitions for all study outcomes are provided in
Table 1.
Data collection and measures
Pre-intervention and post-intervention surveys will be
delivered to the participants’ mobile devices and com-
pleted using Survey Star@ (Wechat, China), a web-based
survey platform that meets industry standards for secur-
ity and functionality. Both surveys were written in
Chinese and verified for clarity and cultural appropriate-
ness with 13 Chinese individuals in Guangdong prov-
ince, including both genders and ages groups.
Recruited individuals will first be assessed for eligibility
by the researcher. Eligible participants will then be asked
to complete the baseline survey on Survey Star@. The
baseline survey will include the following domains:
sociodemographic characteristics, including migrant sta-
tus; access to healthcare at HKU-SZH; trust in health-
care providers; knowledge of and attitudes towards
HCV; and risk of contracting HCV. Migrant status will
be defined based on the definition of internal migrant
from the National Bureau of Statistics of China [23].
Trust in healthcare providers will be assessed using three
items previously used to measure provider trust in
young Chinese men [15]. Stigma towards HCV will be
assessed using a combination of items adapted from the
Toronto. Risk of contracting HCV was assessed using 8
items typically used by HKU-SZH providers for assessing
HCV risk.
Table 1 Primary and secondary outcomes with definitions
Primary Outcome Definition
Confirmed HCV testing uptake Participants that complete HCV testing as confirmed by medical records at HKU-SZH or other public fa-
cility in Shenzhen within 4 weeks of enrollment
Secondary Outcomes Definitions
Self-reported HCV testing uptake Participants that complete HCV testing within 4 weeks of enrollment, self-reported in follow-up survey
Followed-up for HCV confirmatory testing Participants that follow-up with a provider at HKU-SZH for HCV RNA diagnostic testing, as confirmed by
medical records at HKU-SZH or other public facility in Shenzhen
Self-reported follow-up for HCV
confirmatory testing
Participants that follow-up with a provider at HKU-SZH or other care facilities in China for HCV RNA
confirmatory testing, self-reported in follow-up survey
Initiated anti-HCV treatment Participants that have a confirmed HCV diagnosis and initiate anti-HCV treatment at HKU-SZH Depart-
ment of Gastroenterology, confirmed by medical records at HKU-SZH or other public facility in
Shenzhen
Completed anti-HCV treatment Participants that complete the full anti-HCV regiment, as confirmed by medical records at HKU-SZH
Diagnosed with chronic liver disease Participants that are diagnosed with chronic liver disease including cirrhosis, advanced cirrhosis, or
hepatocellular carcinoma at any point during the study, as confirmed by medical records at HKU-SZH
Followed-up with Liver Clinic for advanced
chronic liver disease
Participants that are diagnosed with advanced chronic liver disease (i.e. advanced cirrhosis) and receive
follow-up care at the Liver Clinic at HKU-SZH, as confirmed by medical records at HKU-SZH
Cured of HCV infection Participants that achieve sustained virological response (SVR), defined as absence of detectable
hepatitis C virus 12 weeks after completion of treatment, confirmed by medical records at HKU-SZH
Returned to primary care for future
screening
Participants that returned to FMPC for services including regular HBV/HCV screening, HBV screening,
HIV screening, other STI screening, as confirmed by medical records at HKU-SZH
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Confidentiality
Baseline and follow-up survey data will be collected on
Survey Star@. For follow-up on HCV testing results at
HKU-SZH or in one of the connected public hospitals in
Shenzhen, patient records in the electronic medical
system will be traced by the research team using self-
reported hospital registration ID and demographic
information. All study data will be encrypted prior to
transmission and will be stored in a secure server and
can be access by login information known only to the re-
search team. Ethics approval is obtained through the
IRB of HKU-SZH (hkuszh201888).
Incentives and compensation
Participants who participate in the study will receive an
incentive totaling to 14.48 USD (100 RMB). During the
testing period, the HCV screening test (serum anti-HCV
antibody) will be reimbursed to participants in either
study arm, after the participant completes the follow-up
survey and the research team confirms the testing re-
cords. Reimbursements will cover up to 4 USD (28
RMB) of testing costs for HCV. The participant will
receive reimbursement only if the demographic informa-
tion on the test results matches the participant’s self-
reported information, and the date of testing falls within
the intervention period.
Monitoring
A researcher will check each survey for completion and
internal consistency. Each participant’s baseline and
follow-up survey and test report will be checked for
consistency of their verified cell phone number and
demographic information. Test results must be con-
firmed by testing records at HKU-SZH or verified based
on participant socio-demographics as reported in their
baseline survey. A telephone number and WeChat ac-
count managed by the research team will be made avail-
able to participants for any questions or concerns that
may come up during the study.
Data analysis
Primary analysis
Participant baseline characteristics will be summarized
using descriptive analyses. The primary analysis will
evaluate whether the crowdsourced internet-based inter-
vention package is superior to standard-of-care in in-
creasing HCV testing uptake among the general public
and target populations in China. The effect of the inter-
vention on HCV testing uptake will be evaluated first
using an intention to treat analysis that includes partici-
pants lost to follow-up. The proportion of participants
with confirmed HCV testing in the intervention and
control arms will be calculated separately using a 95%
binomial proportion confidence interval (CI). The
proportion of testing uptake between intervention and
control arms will be compared using chi square test. Lo-
gistic regression adjusted with potential confounders will
be applied to confirm the effect of intervention on the
outcomes. Moreover, multiple logistic regression will be
conducted to evaluate the effect of the following baseline
factors on HCV testing uptake: previous health care ser-
vice utilization behavior; trust in physicians and the
health care system; knowledge of and access to health-
care services; membership in groups at high risk for
HCV.
Missing data plan
Any participants lost to follow-up will be included. If an
outcome is missing for < 15% of participants, analyses
will use a complete-case approach. If an outcome is
missing for ≥15% of participants, analyses will use mul-
tiple imputation.
Secondary analyses
Participants in the control and intervention arms will
also be compared for differences in proportion of partic-
ipants achieving secondary outcomes: number requiring
referral for HCV confirmatory testing; number that re-
ceive confirmed diagnosis for HCV; number that attend
follow-up visits at HKU-SZH for HCV treatment; num-
ber that achieve HCV cure.
Discussion
Historically, HCV prevalence in China has been low, yet
data suggests that that the HCV prevalence in China is
rising across age groups [5, 24]. This may be attributed
to that HCV currently does not have a preventive vac-
cine, and there is poor public awareness of the virus. As
such, the HCV care continuum in China should be ad-
dressed urgently. However, according to a recent sys-
tematic review, few studies have evaluated interventions
to increase HCV testing or treatment uptake [25]. Add-
itionally, prior studies have targeted special populations
such as people who use drugs (PWUD) and MSM, and
have been limited to high risk group in high-income
countries [25]. Few controlled trials have been con-
ducted among the general population in low- or middle-
income countries with high prevalence of viral hepatitis.
Our study is the first to utilize crowdsourcing for viral
hepatitis testing and linkage-to-care in a general popula-
tion. Our study be conducted in context of the new and
evolving primary care system in China, a middle-income
country that is endemic for HCV, but where public and
professional knowledge about HCV is limited. The find-
ings will contribute significantly to the existing literature
on viral hepatitis testing in the primary care setting.
Crowdsourced images promoted through social media
platforms have demonstrated efficacy for increasing HIV
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screening and condom use while simultaneously increas-
ing community engagement and knowledge about the
respective issue [11, 12]. Crowdsourcing also has the po-
tential to address sensitive issues associated with mar-
ginalized populations such as MSM [13]. However,
despite the high rate of social media and technology use
China crowdsourcing may have limited reach to certain
individuals. These overlooked individuals are likely to be
part of the vulnerable population such as PWUD or
people with mental health disorders, or older people
with low technological literacy or social media use. Since
the participation in our study requires the use of a
smartphone and knowledge of social media, the study
will exclude those who do not use these services. The re-
cruitment of the targeted study population based on an
establishing hospital setting would form a limitation as
participants would have been engaged in medical care or
specific treatment. Individuals who are distrustful of or
disengaged from medical care are less likely to be re-
cruited. Finally, our study does not directly address the
lack of primary provider training in China’s HCV care
continuum [9].
The findings from this study can still inform future de-
cisions and policies to improve HCV care training for
primary care providers in China and shape the future
role of China’s primary care system in public health
campaigns.
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